Villanova Investment Management Co LLC Sells 37,445 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Villanova Investment Management Co LLC reduced its position in Supernus Pharmaceuticals by 65.7%, leaving them with 19,587 shares valued at approximately $641,000.
• Several other hedge funds have modified their stakes in Supernus, with Armistice Capital LLC increasing its holdings by 7.4% to 5.2 million shares valued at $170.2 million.
• Supernus Pharmaceuticals received upgraded ratings from Wall Street firms, with Cantor Fitzgerald raising its price objective from $42.00 to $46.00 and two analysts rating the stock as a Buy.

Villanova Investment Management Co LLC trimmed its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 65.7% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,587 shares of the specialty pharmaceutical company's stock after selling 37,445 shares during the period. Supernus Pharmaceuticals accounts for about 1.8% of Villanova Investment Management Co LLC's investment portfolio, making the stock its 22nd largest position. Villanova Investment Management Co LLC's holdings in Supernus Pharmaceuticals were worth $641,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SUPN. Armistice Capital LLC grew its holdings in Supernus Pharmaceuticals by 7.4% in the 1st quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock valued at $170,169,000 after buying an additional 360,000 shares during the last quarter. Woodline Partners LP grew its holdings in Supernus Pharmaceuticals by 124.8% in the 4th quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock valued at $15,326,000 after buying an additional 235,257 shares during the last quarter. GW&K Investment Management LLC grew its holdings in Supernus Pharmaceuticals by 14.6% in the 1st quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock valued at $45,275,000 after buying an additional 176,091 shares during the last quarter. Nuveen LLC acquired a new stake in Supernus Pharmaceuticals in the 1st quarter valued at approximately $4,393,000. Finally, Millennium Management LLC grew its holdings in Supernus Pharmaceuticals by 370.5% in the 1st quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company's stock valued at $4,695,000 after buying an additional 112,886 shares during the last quarter.

Supernus Pharmaceuticals Trading Down 2.6%

SUPN stock traded down $1.20 during trading on Friday, hitting $45.46. The company had a trading volume of 415,075 shares, compared to its average volume of 624,694. The company has a fifty day moving average price of $39.42 and a two-hundred day moving average price of $34.60. The company has a market cap of $2.55 billion, a P/E ratio of 39.53 and a beta of 0.79. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $46.78.

Insiders Place Their Bets

In related news, CFO Timothy C. Dec sold 11,780 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $44.49, for a total value of $524,092.20. Following the sale, the chief financial officer owned 1,246 shares of the company's stock, valued at $55,434.54. The trade was a 90.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bethany Sensenig sold 5,369 shares of the business's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.25, for a total value of $226,840.25. The disclosure for this sale can be found here. Insiders have sold 241,506 shares of company stock worth $10,466,794 over the last quarter. Corporate insiders own 8.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Piper Sandler raised their target price on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a report on Friday, August 29th. Cantor Fitzgerald lifted their price objective on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Finally, Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, Supernus Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $43.00.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.